Exeporfinium chloride is under clinical development by Destiny Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Exeporfinium chloride’s likelihood of approval (LoA) and phase transition for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections took place on 26 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Exeporfinium chloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Exeporfinium chloride overview

Exeporfinium chloride (XF-73) is under development for the prevention of post-surgical Staphylococcal infections, hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections and Staphylococcal respiratory infections such as hospital and ventilator-associated pneumonia (HVAP) methicillin-resistant S. aureus (MRSA), methicillin-sensitive S. aureus (MSSA), hospital associated-MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA), daptomycin resistant S. aureus, low- and high-level mupirocin-resistant S. aureus, linezolid-resistant MRSA, superficial skin infections caused by bacteria, vancomycin-intermediate S. aureus (VISA), diabetic foot infections, diabetic foot ulcers, oral mucositis and fungal infections such as candidoses. The drug candidate is administered through intranasal route as a gel formulation, topical, oral and inhalation (throat) route. It is a new chemical entity (NCE) and is being developed based on XF platform technology.

Destiny Pharma overview

Destiny Pharma, formerly Destiny Pharma, is a drug development and discovery company. It offers commercial exploitation and clinical development of the antibacterial products. The company provides XF drug platform to address multi drug resistant microbial pathogens that cause infections. Its pipeline products includes NTCD-M3, XF-73 and SPOR-COV. Destiny Pharma‘s products find applications for the treatment of clostridioides difficile infections, post surgical infections, dermal infections and COVID-19. The company has its operations through a network of industries, governments and academia. Destiny is headquartered in Brighton, East Sussex, the UK.

Quick View Exeporfinium chloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Exeporfinium chloride
Administration Pathway
  • Inhalational
  • Nasal
  • Oral
  • Topical
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Infectious Disease
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.